SciSparc Ltd. Regains Compliance with Nasdaq Listing Rule 5550(a)(2)

SciSparc Ltd., a clinical-stage pharmaceutical company, has regained compliance with Nasdaq's Listing Rule 5550(a)(2) after maintaining a minimum bid price of $1.00 per share for 10 consecutive business days. This milestone was confirmed by a written notice from The Nasdaq Stock Market LLC on July 18, 2025. The Company's regain of compliance marks the closure of the prior bid price deficiency matter, as per Nasdaq's consideration. SciSparc's focus on developing therapies for central nervous system disorders, including Tourette Syndrome, Alzheimer's disease, and autism, remains unwavering.

Key Takeaways:

• SciSparc Ltd. has regained compliance with Nasdaq Listing Rule 5550(a)(2) after achieving a minimum bid price of $1.00 per share for 10 consecutive business days.
• The Company received a written notice from The Nasdaq Stock Market LLC on July 18, 2025, confirming their compliance with the rule.
• SciSparc's regain of compliance marks the closure of the prior bid price deficiency matter, as per Nasdaq's consideration.
• The Company will continue to focus on developing therapies for central nervous system disorders, including SCI-110 for Tourette Syndrome, SCI-110 for Alzheimer's disease, and SCI-210 for autism.
• SciSparc holds a controlling interest in a subsidiary that focuses on the sale of hemp seeds' oil-based products on the Marketplace.

Statistics:

• Date of written notice from The Nasdaq Stock Market LLC: July 18, 2025
• Number of consecutive business days required for compliance: 10
• Minimum bid price required for compliance: $1.00 per share
• Therapeutic areas focused by SciSparc: central nervous system, including Tourette Syndrome, Alzheimer's disease, autism, and status epilepticus

Sources:

• GLOBE NEWSWIRE
• Nasdaq Stock Market LLC
• SciSparc Ltd. (Nasdaq: SPRC)